Arachidonic Acid Treatment Against Schistosomiasis Infection in Children

NCT ID: NCT02144389

Last Updated: 2014-05-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

335 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized Controlled Trial:

The investigational materials used in this trial were administered to subjects each day by trained clinicians.

Primary Objectives:

* assess the effect of dietary supplementation with arachidonic acid on the cure rates for Schistosomiasis mansoni with and without concomitant treatment with praziquantel.
* assess the safety of dietary supplementation using arachidonic acid in children with clinically confirmed schistosomiasis mansoni infection.

Secondary objective:

* to measure changes in total phospholipids in plasma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schistosomiasis Bilharzia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Praziquantel (PZQ)

A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.

Group Type ACTIVE_COMPARATOR

Praziquantel (PZQ)

Intervention Type DRUG

40 mg/kg, a single dose, administered orally

1 g of corn/soybean oil (50%/50%), administered orally

Arachidonic acid (ARA)

A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.

Group Type EXPERIMENTAL

Arachidonic acid (ARA)

Intervention Type DIETARY_SUPPLEMENT

ARA (40% of total fatty acid)

PZQ + ARA

A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.

Group Type EXPERIMENTAL

PZQ+ARA

Intervention Type DIETARY_SUPPLEMENT

A single dose of PZQ administered seven days in advance of initial treatment with ARA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Praziquantel (PZQ)

40 mg/kg, a single dose, administered orally

1 g of corn/soybean oil (50%/50%), administered orally

Intervention Type DRUG

Arachidonic acid (ARA)

ARA (40% of total fatty acid)

Intervention Type DIETARY_SUPPLEMENT

PZQ+ARA

A single dose of PZQ administered seven days in advance of initial treatment with ARA.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Praziquantel (generic) Biltricide trematodicide ARASCO Microbial arachidonic acid-rich oil ARASCO praziquantel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* consent from parent or legal guardian
* clinically confirmed schistosomiasis

Exclusion Criteria

* not infected with schistosomiasis
* less than 6 or greater than 15 years of age
Minimum Eligible Age

6 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Liver Institute, Egypt

OTHER

Sponsor Role collaborator

Cairo University

OTHER

Sponsor Role collaborator

High Institute of Public Health, Egypt

OTHER

Sponsor Role collaborator

DSM Nutritional Products, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rashika El Ridi

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Sahar Selim, Ph.D.

Role: STUDY_DIRECTOR

National Liver Institute, Menoufiya University

Rashida Barakat, Ph.D.

Role: STUDY_DIRECTOR

High Institute of Public Health, Alexandria University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Liver Institute, Menoufiya University,

Shebin El-Kom, Monufia Governorate, Egypt

Site Status

Tropical Health Department, High Institute of Public Health, Alexandria University

Alexandria, , Egypt

Site Status

Cairo University

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Barakat R, Abou El-Ela NE, Sharaf S, El Sagheer O, Selim S, Tallima H, Bruins MJ, Hadley KB, El Ridi R. Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regions. Am J Trop Med Hyg. 2015 Apr;92(4):797-804. doi: 10.4269/ajtmh.14-0675. Epub 2015 Jan 26.

Reference Type DERIVED
PMID: 25624403 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-1054

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

S. Japonicum and Pregnancy Outcomes
NCT00486863 COMPLETED PHASE2